House dust mite allergy vaccine - Stallergenes Greer plc

Drug Profile

House dust mite allergy vaccine - Stallergenes Greer plc

Alternative Names: Dust mite extract immunotherapy - Stallergenes Greer plc; HDM immunotherapy - Stallergenes Greer plc; House dust mite immunotherapy - Stallergenes Greer plc

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Greer Laboratories
  • Developer Stallergenes Greer plc
  • Class Allergens; Allergy immunotherapies; Antiallergics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Allergic rhinitis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Allergic-rhinitis in USA (Sublingual, Drops)
  • 17 Mar 2009 Efficacy and adverse events data from a phase I trial in Allergic rhinitis presented at the 65th Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2009) ,
  • 31 Dec 2005 Phase-I clinical trials in Allergic rhinitis in USA (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top